[Hemolytic uremic syndrome associated to shigatoxin producing Escherichia coli in Chilean children: clinical and epidemiological aspects].

Rev Chilena Infectol

Universidad de Chile, Facultad de Medicina, Instituto de Ciencias Biomédicas-ICBM, Programa de Microbiología y Micología.

Published: December 2008

Clinical and epidemiological aspects of shigatoxin producing E. coli (STEC) infections and hemolytic uremic syndrome (HUS) are reviewed. Surveillance results from 14 sentinel centers during 2000-2002 showed a mean incidence rate of 3.4 HUS cases per 100,000 children, with the highest incidence in the 6 to 28 month age group. Disease is endemic with summer peaks. Between 1988 and 2002 we obtained the clinical characteristics of a group of 119 HUS children with the following results: mean age 16 months, bloody diarrhea 57.8%, no previous diarrhea 9%, 60% received antibiotics, 72% had oligoanuria, 53% required dialysis, 15% had seizures and 31% had dizziness; mortality was 3%. Four foodborne outbreaks have been detected in Santiago, two outbreaks occurred in household settings, one in a Day Care Center and one in a Neonatal Unit. Recommendations for diagnosis, treatment and prevention of STEC infections, including potential vaccines are discussed.

Download full-text PDF

Source

Publication Analysis

Top Keywords

uremic syndrome
8
shigatoxin producing
8
clinical epidemiological
8
stec infections
8
[hemolytic uremic
4
syndrome associated
4
associated shigatoxin
4
producing escherichia
4
escherichia coli
4
coli chilean
4

Similar Publications

In glomerulopathies, endothelial dysfunction and the presence of histological vascular lesions such as thrombotic microangiopathy, arteriolar hyalinosis, and arteriosclerosis are related to a severe clinical course and worse renal prognosis. The endothelial cell, which naturally has anti-inflammatory and anti-thrombotic regulatory mechanisms, is particularly susceptible to damage caused by various etiologies and can become dysfunctional due to direct/indirect injury or a deficiency of protective factors. In addition, endothelial regulation and protection involve participation of the complement system, factors related to angiogenesis, the renin-angiotensin system (RAS), endothelin, the glycocalyx, the coagulation cascade, interaction between these pathways, interactions between glomerular structures (the endothelium, mesangium, podocyte, and basement membrane) and interstitial structures (tubules, arterioles and small vessels).

View Article and Find Full Text PDF

CRISPR/Cas Systems as Diagnostic and Potential Therapeutic Tools for Enterohemorrhagic .

Arch Immunol Ther Exp (Warsz)

January 2025

Department of Animal, Veterinary, and Food Science, University of Idaho, Moscow, Idaho, USA.

Following its discovery as an adaptive immune system in prokaryotes, the clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPR-associated proteins (Cas) system has been developed into a multifaceted genome editing tool. This review compiles findings aimed at implementation of this technology for selective elimination or attenuation of enterohemorrhagic (EHEC). EHEC are important zoonotic foodborne pathogens that cause hemorrhagic colitis and can progress to the life-threatening hemolytic uremic syndrome (HUS).

View Article and Find Full Text PDF

Case of COVID-19 infection-induced complement-mediated thrombotic microangiopathy.

Med J Armed Forces India

December 2024

Senior Advisor (Medicine) & Nephrologist, Base Hospital Delhi Cantt, New Delhi, India.

The SARS-CoV-2 virus can cause thrombotic microangiopathy (TMA) by alternate pathway activation. We present a case of a young female patient who presented with fever and dialysis-dependent acute kidney injury. On evaluation, she was diagnosed with COVID-19-induced complement-mediated thrombotic microangiopathy (CM-TMA).

View Article and Find Full Text PDF

Outcomes in patients with thrombotic microangiopathy associated with a trigger following plasma exchange: A systematic literature review.

Transfus Apher Sci

December 2024

Alexion, AstraZeneca Rare Disease, 121 Seaport Blvd, Boston, MA 02210, USA. Electronic address:

Plasma exchange (PE) outcomes in patients with trigger-associated thrombotic microangiopathy (TMA) have not been comprehensively reviewed. Embase and MEDLINE® were searched on 03/14/2022 for English language articles published after 2007, alongside a congress materials search (2019-2022; PROSPERO: CRD42022325170). Studies with patients with trigger-associated TMA (excluding thrombotic thrombocytopenic purpura, 'typical' hemolytic uremic syndrome caused by Shiga toxin-producing Escherichia coli, post-partum TMA, and TMAs with known genetic cause) who received PE or plasma infusion (PI) and reported treatment response (including measures), safety, patient-/caregiver-reported outcomes, or economic burden data were examined.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!